Analyst Ratings for Allbirds
Allbirds (NASDAQ:BIRD) has observed the following analyst ratings within the last quarter:
Cowen & Co. Maintains Outperform on Allbirds, Lowers Price Target to $5
Cowen & Co. analyst John Kernan maintains Allbirds (NASDAQ:BIRD) with a Outperform and lowers the price target from $7 to $5.
Morgan Stanley Downgrades Allbirds to Equal-Weight, Lowers Price Target to $5
Morgan Stanley analyst Alex Straton downgrades Allbirds (NASDAQ:BIRD) from Overweight to Equal-Weight and lowers the price target from $12 to $5.
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.
Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.
Allbirds Q2 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $78.20M Beat $77.77M Estimate
Allbirds (NASDAQ:BIRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. The company reported quarterly sales of $78.20 million which beat the analyst